{
  "docId": "019de075-e109-770f-8f32-3054686041b6",
  "docSlug": "9819f3512e565b918c6cfc8e3688cfb2",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Spyre Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 38,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 16,
  "notes": "The slide uses two distinct data visualizations: a table for clinical safety metrics and a bar chart for ADA rates.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/18",
  "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6",
  "deckJsonHref": "/decks/019de075-e109-770f-8f32-3054686041b6.json",
  "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.42,
        "x": 0.54,
        "y": 0.295
      },
      "kind": "chart",
      "text": "ADA rates for YTE vs WT antibodies",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b5c4d5b1-2614-448d-9533-fedda93b3220",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.02,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Source: 1Entyvio prescribing information; 2Rocca, A, et al. Int J of Mol Sci, 2021; 3Domachowske NEJM 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a1d79771-a330-46d1-8c74-33a846cd32a6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.45,
        "x": 0.02,
        "y": 0.295
      },
      "kind": "table",
      "text": "Vedolizumab vs Placebo safety metrics including infection, malignancy, and immunogenicity rates.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8732887f-578d-4bf5-b6eb-d293f99f7673",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "SPY001 is designed to match vedolizumab’s favorable safety profile and low rate of ADAs",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a11d7488-8ce5-4502-8708-0f1887a9254e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "9a1e7132-faf0-4b47-9308-b4d7106219b5",
      "evidence": "chart/bar-vertical: ADA rates for YTE vs WT antibodies",
      "confidence": 0.7
    },
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "08755139-f714-4b5e-9e07-03fff48351f7",
      "evidence": "table/data: Vedolizumab vs Placebo safety metrics including infection, malignancy, and immunogenicity rates.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}